Impact of definitive radiotherapy on metabolic response measured with 68 Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer
The Prostate · 2024
DOI: 10.1002/pros.24775 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Cem Onal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Baskent University, Adana, Turkiye. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Gallium Radioisotopes, Prostate-Specific Antigen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
To assess the early metabolic response of the primary tumor using Gallium‐68 ( 68 Ga)‐labeled‐prostate‐specific membrane antigen positron emission tomography ( 68 Ga‐PSMA‐PET/CT), as well as the relationship between PSMA change in the primary tumor and PSA response after definitive radiotherapy (RT), either alone or in combination with androgen deprivation therapy (ADT) in intermediate risk prostate cancer (IR‐PCa) patients.
Methods
The clinical data of 71 IR‐PCa patients treated with RT alone (36 patients, 50.7%) or RT and ADT (35 patients, 49.3%) were retrospectively analyzed. The difference between pre‐ and Posttreatment primary tumor PSMA expression and serum PSA values measured 4 months after completion of treatment were compared between treatment arms. Correlation between primary tumor metabolic response and serum PSA changes was analyzed.
Results
The median duration between pre‐ and Posttreatment 68 Ga‐PSMA‐PET/CT for the entire patient population was 6.9 months (range, 5.6–8.4 months), and it was similar in both treatment arms. A decrease in primary tumor maximum standardized uptake value (SUVmax) was seen in 66 patients (93.0%), with a median value of 61.2%, which is significantly lower in patients undergoing RT alone than those undergoing RT and ADT (45.1 ± 30.6% vs. 59.1 ± 24.7%; p = 0.004). The complete metabolic response rate was significantly higher in patients undergoing RT and ADT than those treated with RT alone (40% vs. 0%; p < 0.001). Although moderate and positive correlation between pretreatment SUVmax and oosttreatment SUVmax was observed, there was no significant correlation between SUV change and PSA change. For patients treated with RT and ADT, posttreatment SUVmax was significantly lower and SUV change was significantly higher in patients with PSA nadir than in those without.
Conclusions
Our preliminary results show that RT, with or without ADT, significantly reduces primary tumor SUVmax and serum PSA levels. Nonetheless, our findings indicate that early treatment response using 68 Ga‐PSMA‐PET/CT is not feasible for those treated with RT alone, and it may only be useful in better distinguishing patients with and without PSA nadir for those who received both RT and ADT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Baskent University, Adana, Turkiye.
- Department of Radiation Oncology, Faculty of Medicine, Baskent University, Ankara, Turkiye.
- Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Baskent University, Adana, Turkiye.
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Cem Onal, Aysenur Elmali
Zitieren
APA
Onal, C., Guler, O. C., Torun, N., Elmali, A., Sutera, P., Deek, M. P., Reyhan, M., Yavuz, M., & Tran, P. T. (2024). Impact of definitive radiotherapy on metabolic response measured with 68 Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer. The Prostate. https://doi.org/10.1002/pros.24775
Vancouver
Onal C, Guler OC, Torun N, Elmali A, Sutera P, Deek MP, et al. Impact of definitive radiotherapy on metabolic response measured with 68 Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer. The Prostate. 2024. doi:10.1002/pros.24775
BibTeX
@article{Onal2024,
author = {Onal, Cem and Guler, Ozan C and Torun, Nese and Elmali, Aysenur and Sutera, Philip and Deek, Matthew P and Reyhan, Mehmet and Yavuz, Melek and Tran, Phuoc T},
title = {Impact of definitive radiotherapy on metabolic response measured with 68 Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24775}
}
EUVIMED